Patents by Inventor Alexander R. Rovira

Alexander R. Rovira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416256
    Abstract: This invention relates to compounds of Formula I that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Application
    Filed: November 11, 2021
    Publication date: December 28, 2023
    Applicant: Janssen Pharamceutica NV
    Inventors: William M. Jones, Alec D. Lebsack, Ronald L. Wolin, Alexander R. Rovira
  • Patent number: 11827634
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: November 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wendy Eccles, Michael D. Hack, William M. Jones, Paul J. Krawczuk, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
  • Publication number: 20230080834
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Application
    Filed: December 13, 2021
    Publication date: March 16, 2023
    Inventors: Wendy Eccles, Michael D. Hack, William M. Jones, Paul J. Krawczuk, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
  • Patent number: 11254673
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Wendy Eccles, Michael D. Hack, Aaron T. Herrmann, William M. Jones, Paul J. Krawczuk, Kevin D. Kreutter, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
  • Publication number: 20210300918
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 30, 2021
    Inventors: J. Kent Barbay, Wenying Chai, Wendy Eccles, Michael D. Hack, Aaron T. Herrmann, William M. Jones, Paul J. Krawczuk, Kevin D. Kreutter, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin